Matricelf Ltd announced today the appointment of Mr. Ron Meron, former CEO of Teva Israel, as a member of the company’s Board of Directors. His nomination as Chairman of the Board will be presented for approval at the upcoming general meeting of shareholders.
This announcement marks another milestone for Matricelf, which recently received preliminary approval from Israel’s Health Ministry to begin compassionate-use trials in eight patients. As part of this breakthrough, by late 2026 or early 2027, the company expects to perform the world’s first implantation of a personalized, engineered human spinal cord in a paralyzed patient, with the aim of enabling them to rise from a wheelchair and walk again.
The company’s revolutionary technology is based on organ engineering research developed at Tel Aviv University by Prof. Tal Dvir, Head of the Sagol Center for Regenerative Biotechnology and Chief Scientist at Matricelf, together with the continued development led by Dr. Tamar Harel Adar, the company’s VP of R&D.
In its filing to the Israel Securities Authority, Matricelf highlighted that Mr. Meron brings decades of extensive experience in the global biomed industry, including proven expertise in leading international corporations, managing complex organizations, formulating growth strategies, driving business development, and entering new markets. His senior leadership roles at Teva, particularly as CEO of Teva Israel, make him one of the most influential and experienced figures in the Israeli life sciences sector.
Ron Meron: "I am proud to join Matricelf, a pioneering company with a truly unique technological platform. I believe the company can provide advanced medical solutions for paralysis caused by spinal cord injury and, in the future, for other severe diseases. I see this role as an opportunity to bridge groundbreaking scientific innovation with global business implementation."
Dr. Alon Sinai, Founder and President of Matricelf: “We are delighted to welcome Ron Meron to Matricelf’s leadership team. His influential experience in business development, strategy, and complex process management in the biomed industry represents a major strategic asset for the company. I am confident that his knowledge, connections, and vision will help advance our roadmap in the coming years and support our mission to lead meaningful change in the field of regenerative medicine.”
This article was written in collaboration with Tel Aviv University.